Results 121 to 130 of about 4,378 (208)

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

, 2022
Steven G Waguespack, Alexander Drilon, Jessica J Lin, Marcia S Brose, Ray McDermott, Mohammed Almubarak, Jessica Bauman, Michela Casanova, Anuradha Krishnamurthy, Shivaani Kummar, Serge Leyvraz, Do-Youn Oh, Keunchil Park, Davendra Sohal, Eric Sherman, Ricarda Norenberg, Josh D Silvertown, Nicoletta Brega, David S Hong, Maria E Cabanillas   +19 more
openalex   +1 more source

Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI

, 2023
Matthieu Carton, Johanna Peña Del Castillo, Jean-Baptiste Colin, Milena Kurtinecz, Marion Feuilly, Gaëlle Pierron, Pierre Arvis, Soumeya Khadidja Khadir, Monika Sparber‐Sauer, Daniel Orbach   +9 more
openalex   +1 more source

Reigniting the Flame for Redifferentiation Strategies in Differentiated Thyroid Cancers: Journey of Tyrosine Kinase Inhibitors to Renewed Radioactive-Iodine Avidity. [PDF]

Endocrinol Metab (Seoul)
Oh JM, Zhu L, Ahn BC.
europepmc   +1 more source

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions. [PDF]

Oncol Res
Rubinstein M, Hong ML, Nanda RK, Jones DT, Aboaid H, Myat YM, Thein KZ.   +6 more
europepmc   +1 more source

Primary secretory carcinoma of thyroid with unusual features mimicking metastasis? [PDF]

Diagn Pathol
Teague J, Ciolino A, Sajisevi M.
europepmc   +1 more source

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

, 2018
Rolf W. Sparidans, Yaogeng Wang, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen   +4 more
openalex   +1 more source

Late Recurrence of Spindle Cell Sarcoma in Association with <i>TPM3::NTRK1</i> Fusion. [PDF]

Int J Surg Pathol
Parisi X, Ghosh A, Wang WL, Cortes-Santiago N, Medeiros LJ.   +4 more
europepmc   +1 more source

Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study) [PDF]

Daniel Orbach, Matthieu Carton, S.K. Khadir, Marion Feuilly, M. Kurtinecz, D Phil, C. Vokuhl, Ewa Kościelniak, Gaëlle Pierron, L. Lemelle, M. Sparber-Sauer   +10 more
openalex   +1 more source

Larotrectinib for solid tumours

Australian Prescriber, 2022
openaire   +2 more sources

Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands. [PDF]

Int J Technol Assess Health Care
Versteeg JW, Stam N, Mantel-Teeuwisse AK, Timmers L, Goettsch W, Leopold C.   +5 more
europepmc   +1 more source